Discovery of Dual FGFR4 and EGFR Inhibitors by Machine Learning and Biological Evaluation

Xingye Chen1, Wuchen Xie1, Yan Yang1

  • 1Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.

Insights

Researchers developed dual kinase inhibitors targeting FGFR4 and EGFR using machine learning. Compound 1 showed potent activity, demonstrating a promising strategy for developing selective antitumor drugs with reduced side effects.

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Drug Discovery

Background:

  • Kinase inhibitors are crucial for antitumor research but face challenges like drug resistance and toxicity.
  • Designing selective multitarget inhibitors offers a potential solution to overcome these limitations.

Purpose of the Study:

  • To discover dual inhibitors targeting Fibroblast Growth Factor Receptor 4 (FGFR4) and Epidermal Growth Factor Receptor (EGFR).
  • To apply machine learning and quantitative structure-property relationship (QSPR) studies for efficient inhibitor design.

Main Methods:

  • Developed QSPR models using Support Vector Machine (SVM), Random Forest (RF), Gradient Boost Regression Tree (GBRT), and XGBoost (XGB).
  • Selected optimal features using the mutual information algorithm.
  • Validated models and predicted activities of compounds from an in-house database.
  • Performed molecular docking and dynamics simulations for selected compound 1.

Main Results:

  • SVM models achieved high predictive accuracy for FGFR4 (R 2 test = 0.80) and EGFR (R 2 test = 0.75).
  • Identified compound 1 as a dual inhibitor with IC 50 values of 86.2 nM for FGFR4 and 83.9 nM for EGFR.
  • Molecular simulations elucidated key interactions between compound 1 and target kinases.

Conclusions:

  • Machine learning-based QSPR models effectively guided the discovery of dual-target inhibitors.
  • This approach shows significant potential for developing selective and effective antitumor therapies.